Privacy Concerns about UAS Missions: A Regression Analysis

Background and Objectives: Unmanned aerial systems (UAS), also known casually as drones, have changed the ways in which many industries conduct business. One prevalent example would be their use by police organizations (local patrols, SWAT, and etc.) to revolutionize their surveillance capabilities. Many major city police commissioners have stated their interests in welcoming the use of unmanned aerial vehicles (UAV). Past studies have analyzed citizen’s emotions in regard to privacy concerns focusing on the amount of time the drones spent patrolling--either twenty-four hours a day or in mission only conditions. The purpose of this study was to determine what variables predict privacy concerns. In other words, do political affiliations, location, or gender affect a participant’s emotions toward their privacy? Methods: Two hundred participants were surveyed through Amazon’s Mechanical Turk (MTurk). They were presented with hypothetical scenarios involving police issued UAV patrols occurring near their residence. Following the scenario, they were asked to rate statements from a validated UAV privacy scale and then complete a set of demographic questions that served as potential predictors.ResultsA linear regression analysis revealed two significant predictors. First, females were more likely to express privacy concerns during the UAS missions compared to their male counterparts (B = .31). Second, people who rated themselves are more conservative also expressed more privacy concerns compared to people who rated themselves as more liberal (B = .30). ConclusionWhen conducting UAS missions in public or near housing residences, it is important to take note of the privacy concerns raised by residents and other citizens in the area.These findings reveal that females and conservative-leaning people tend to have more privacy concerns about UAS missions than male, liberal-leaning people. Keywords: Unmanned aerial systems/vehicles, Mechanical Turk, privacy scale, drones, moderatio

A Preliminary Comparison of Pilots\u27 Weather Minimums and Actual Decision-Making

Adverse weather conditions remain a leading contributing factor in general aviation accidents. In compromising situations, such as severe weather, pilots continue to make decisions, which endanger themselves, passengers, and the aircraft. Although technology and training have lowered the risks associated with poor decision making by aviators, they are often still faced with scenarios requiring split second judgments. A countermeasure to these risks is the use of personal weather minimums by pilots. The purpose of this study was to examine pilot’s decision-making and performance, while flying an instrument approach, under extreme conditions of low visibility and ceiling as based on their stated personal minimums. A sample of 35 flight students with instrument ratings was recruited from a large university flight program located in the southeastern part of the United States. Participants were asked a series of pre-test questions, including their personal weather minimums, and then flew an ILS instrument approach on an Elite-1000 flight simulator at the subject university. The findings indicate approximately eighty percent of participants, on average, descended nearly two-hundred feet below their stated personal minimums before aborting the approach. Furthermore, forty percent of them also flew twenty-five feet below the federal requirement (200 feet above ground level) before aborting the approach. These results are pertinent to advance our understanding of the many different variables affecting pilot’s decision making. Understanding these outcomes will progress our initiatives to ensure safer air travel, while improving pilot’s competence and their passenger’s confidence

Implementation of BIM and lean construction in offsite housing construction: evidence from the UK

This is an accepted manuscript of an article published by IGLC in the Proceedings of the 29th Annual Conference of the International Group for Lean Construction (IGLC29), Alarcon, L.F. and González, V.A. (eds.), available online: https://iglc.net/Papers/Details/1906 The accepted version of the publication may differ from the final published version.The benefits of integrating Lean construction (LC) and Building Information Modelling (BIM) have been discussed in recent research studies. However, the effects of implementing these methodologies as an integrated approach in offsite housing construction (OSHC) processes have not been explored in the UK. This research aims at assessing the current situation of the implementation of BIM and LC in OSHC in the UK. A quantitative research method was adopted in the study and thirty-two questionnaire survey responses were received from professionals and practitioners of Lean, BIM and offsite methodologies in the UK construction industry. The study found that there is increasing use of LC and BIM in the development of OSHC projects in the UK. It further reveals that these two methodologies when appropriately implemented can bring several benefits. This study sheds light on the current status of implementation of BIM and LC in OSHC and the benefits of the implementation of both BIM and LC in OSHC processes in the UK

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment : study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

Background: New targeted therapies and improved treatment strategies have dramatically improved the outcomes of patients with rheumatoid arthritis (RA). However, it is unknown whether different early aggressive interventions can induce stable remission or a low-active disease state that can be maintained with conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy, and whether they differ in efficacy and safety. The Nordic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) study will assess and compare (1) the proportion of patients who achieve remission in a head-to-head comparison between csDMARD plus glucocorticoid therapy and three different biological DMARD (bDMARD) therapies with different modes of action and (2) two de-escalation strategies in patients who respond to first-line therapy. Methods/design: In a pragmatic, 80-160-week, multicenter, randomized, open-label, assessor-blinded, phase 4 study, 800 patients with early RA (symptom duration less than 24 months) are randomized 1: 1: 1: 1 to one of four different treatment arms: (1) aggressive csDMARD therapy with methotrexate + sulphasalazine + hydroxychloroquine + i. a. glucocorticoids (arm 1A) or methotrexate + prednisolone p.o. (arm 1B), (2) methotrexate + certolizumab-pegol, (3) methotrexate + abatacept, or (4) methotrexate + tocilizumab. The primary clinical endpoint is the proportion of patients reaching Clinical Disease Activity Index (CDAI) remission at week 24. Patients in stable remission over 24 consecutive weeks enter part 2 of the study earliest after 48 weeks. Patients not achieving sustained CDAI remission over 24 consecutive weeks, exit the study after 80 weeks. In part 2, patients are re-randomized to two different de-escalation strategies, either immediate or delayed (after 24 weeks) tapering, followed by cessation of study medication. All patients remain on stable doses of methotrexate. The primary clinical endpoint in part 2 is the proportion of patients in remission (CDAI Discussion: NORD-STAR is the first investigator-initiated, randomized, early RA trial to compare (1) csDMARD and three different bDMARD therapies head to head and (2) two different de-escalation strategies. The trial has the potential to identify which treatment strategy to apply in early RA to achieve the best possible outcomes for both patients and society.Peer reviewe

Personal Safety Culture: A New Measure for General Aviation Pilots

Safety culture has been a subject of research for over three decades and is now widely accepted as a critical component of organizational safety programs both domestically and internationally. Through the development of a healthy safety culture, aviation organizations can improve safety processes, reduce mishaps, and mitigate risk more effectively. This is done through the holistic team efforts of an organization’s members and the organization’s leadership. How about aviators who are not part of an organization? Is it possible to identify a personal safety culture defined outside of the traditional organization? And, is it possible to create an instrument allowing pilots to conduct a self-assessment of their personal safety culture? The current research seeks to address these questions by developing such an instrument to measure personal safety culture in General Aviation pilots. The first version of the instrument was developed using resources from prior research studies and a literature review of over 160 publications. It was initially sent to experts in civilian aviation, academia and military sectors who conducted face validity assessments. Once revised, the instrument was tested using a sample drawn from a large southeastern university in the United States. All pilots were required to hold at least a private pilot certificate. A factor analysis conducted on the results of the preliminary study indicate factors that account for a significant amount of the variance in the model. These results are presented with recommendations for application of the self-assessment and thoughts on future research

Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency

Tyrosine hydroxylase catalyses the hydroxylation of L-tyrosine to l-DOPA, the rate- limiting step in the synthesis of catecholamines. Mutations in the TH gene encoding tyrosine hydroxylase are associated with the autosomal recessive disorder tyrosine hydroxylase deficiency, which manifests phenotypes varying from infantile parkinsonism and DOPA-responsive dystonia, also termed type A, to complex encephalopathy with perinatal onset, termed type B. We generated homozygous Th knock-in mice with the mutation Th-p.R203H, equivalent to the most recurrent human mutation associated with type B tyrosine hydroxylase deficiency (TH-p.R233H), often unresponsive to l-DOPA treatment. The Th knock-in mice showed normal survival and food intake, but hypotension, hypokinesia, reduced motor coordination, wide-based gate and catalepsy. This phenotype was associated with a gradual loss of central catecholamines and the serious manifestations of motor impairment presented diurnal fluctuation but did not improve with standard l-DOPA treatment. The mutant tyrosine hydroxylase enzyme was unstable and exhibited deficient stabilization by catecholamines, leading to decline of brain tyrosine hydroxylase-immunoreactivity in the Th knock-in mice. In fact the substantia nigra presented an almost normal level of mutant tyrosine hydroxylase protein but distinct absence of the enzyme was observed in the striatum, indicating a mutation-associated mislocalization of tyrosine hydroxylase in the nigrostriatal pathway. This hypomorphic mouse model thus provides understanding on pathomechanisms in type B tyrosine hydroxylase deficiency and a platform for the evaluation of novel therapeutics for movement disorders with loss of dopaminergic input to the striatum

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study

AIM: The SARS-CoV-2 pandemic has provided a unique opportunity to explore the impact of surgical delays on cancer resectability. This study aimed to compare resectability for colorectal cancer patients undergoing delayed versus non-delayed surgery. METHODS: This was an international prospective cohort study of consecutive colorectal cancer patients with a decision for curative surgery (January-April 2020). Surgical delay was defined as an operation taking place more than 4 weeks after treatment decision, in a patient who did not receive neoadjuvant therapy. A subgroup analysis explored the effects of delay in elective patients only. The impact of longer delays was explored in a sensitivity analysis. The primary outcome was complete resection, defined as curative resection with an R0 margin. RESULTS: Overall, 5453 patients from 304 hospitals in 47 countries were included, of whom 6.6% (358/5453) did not receive their planned operation. Of the 4304 operated patients without neoadjuvant therapy, 40.5% (1744/4304) were delayed beyond 4 weeks. Delayed patients were more likely to be older, men, more comorbid, have higher body mass index and have rectal cancer and early stage disease. Delayed patients had higher unadjusted rates of complete resection (93.7% vs. 91.9%, P = 0.032) and lower rates of emergency surgery (4.5% vs. 22.5%, P < 0.001). After adjustment, delay was not associated with a lower rate of complete resection (OR 1.18, 95% CI 0.90-1.55, P = 0.224), which was consistent in elective patients only (OR 0.94, 95% CI 0.69-1.27, P = 0.672). Longer delays were not associated with poorer outcomes. CONCLUSION: One in 15 colorectal cancer patients did not receive their planned operation during the first wave of COVID-19. Surgical delay did not appear to compromise resectability, raising the hypothesis that any reduction in long-term survival attributable to delays is likely to be due to micro-metastatic disease

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio